The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes.
By G. Gaich, J. Chien, H. Fu, L. Glass, M. Deeg, William L. Holland, A. Kharitonenkov, T. Bumol, Holger K. Schilske, D. Moller. Cell Metabolism, 2013
854 citations recorded by the source corpus.
Subfields: Molecular Biology
View Paper: https://www.semanticscholar.org/paper/482de89dc9a8b0460de323db5b4150a6bf76b578
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Gerald I. Shulman
- V. Samuel
- A. Chait
- Laura J. den Hartigh
- Haiming Cao
- Ralph DeFronzo
- Max C. Petersen
Citations in the corpus
- Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease (2020, background): “In stark contrast to these effects of physiological FGF21, pharmacological administration of FGF21 in humans and non-human primates reduces blood glucose, insulin, triglycerides, and LDL cholesterol, and increases HDL cholesterol (142, 463, 464).”
- Current and future pharmacological therapies for NAFLD/NASH (2017, background): “A RCT in a small group of obese T2DM patients with FGF-21 found significant improvement in lipid profiles as well as weight loss, reduced insulin levels, and raised adiponectin [84].”
- FGF/FGFR signaling in health and disease (2020, background): “To date, LY2405319 has been tested through phase I clinical trial to reduce body weight and fasting insulin, and is noteworthy in improving dyslipidemia in patients with type 2 diabetes mellitus.(697) Another FGF21 variant is reconstructed through the introduction of pacetyl phenylalanine into the N”
- Metabolically Healthy Obesity (2020, background): “In contrast, healthy expansion of AT leads to metabolically healthy obesity through an increased AT storage capacity (serving as a safe “metabolic sink”) and the secretion of a beneficial adipokine profile (eg, adiponectin, FGF-21, leptin) (adapted from references (60, 61).”
- The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. (2016, background): “In this regard, FGF-21 has been shown to be effective in reducing hepatic steatosis and reversing insulin resistance in rodents (124) and is now in clinical trials (125).”